Sort   by:  
 Page size 
ProteomicsDifferential MAPK Phosphorylation of Connexin43
MAPK family members are known to phosphorylate the c-terminal tail of connexin43 (cx43), however little is known about the preference of different MAPKs for specific cx43 phosphorylation sites. We utilized mass spectrometry to determine the cx43 sites phosphorylated in kinase assays by Erk, JNK, and...
ORGANISM(S): Homo sapiens (Human) Rattus norvegicus (Rat) 
2025-01-14 | PXD042575 | Pride
Erk Kinase assay Connexin43 P38 Gja1 Jnk Mapk 
ProteomicsOptogenetic Src Temporal Signaling
The purpose of this study was to characterize a novel optogenetic kinase system, a Light-Regulated (LightR) switch domain, designed to improve spatiotemporal control of signaling. Using LC-MS/MS, tyrosine phosphorylation was measured after 10 seconds, 30 seconds, 1 minute, 5 minutes and 60 minutes o...
ORGANISM(S): Homo sapiens (Human) 
2020-10-20 | PXD018162 | Pride
Hela Optogenetics Src Phosphotyrosine Lc-ms/ms 
ProteomicsSurprisal Analysis of Patient-Specific Signaling Networks in TNBC
The present study sought to combine surprisal analysis, utilizing systems-level data to predict unbalanced processes in each patient tumor, with quantitative analysis of tyrosine phosphorylation mediated signaling networks to identify potential therapeutic targets and therapeutic combinations in TNB...
ORGANISM(S): Homo sapiens (Human) 
2025-01-14 | PXD042640 | Pride
Surprisal analysis Pdx Triple negative breast cancer Phosphoproteomics Passs 
ProteomicsCharacterization of WSD-0922 Signaling
The present pre-clinicial study sought to evaluate the novel EGFR inhibitor WSD-0922. We employed flank and orthotopic patient derived xenograft (PDX) models to characterize WSD-0922 and compare its therapeutic efficacy to erlotinib, a potent EGFR inhibitor that failed to provide clinical benefit fo...
ORGANISM(S): Homo sapiens (Human) 
2023-06-21 | PXD032974 | Pride
Blood-brain barrier Glioblastoma Erlotinib Wsd-0922 Egfr 
Sort   by:  
 Page size